References
PD
ADVERSE EVENTS
Teverelix DP dose and regimen and evaluation days in the Phase 2 clinical trials. Yellow box = subcutaneous (SC) injection; green box = intramuscular (IM) injection; orange box = assessment days for teverelix, testosterone and luteinizing hormone. D = day; LH = luteinizing hormone; PSA = prostate-specific antigen; Tev = teverelix; T = testosterone. Mean teverelix DP concentration (ng/mL)(+SEM) vs. time (days). IM = intramuscular; SC = subcutaneous.Mean total testosterone (ng/mL), luteinizing hormone (IU/L) and PSA (ng/mL)(+SEM) vs. time (days). IM = intramuscular; LH = luteinizing hormone; PD, pharmacodynamics; PSA = prostate-specific antigen; SC = subcutaneous; T = testosterone.Patient baseline characteristics (per-protocol population).BMI = body mass index; D = day; IM = intramuscular; SC = subcutaneous; SD = standard deviation.Mean onset and duration of castration.D = day; IM = intramuscular; SC = subcutaneous. Overview of adverse events.D = day; IM = intramuscular; SC = subcutaneous. 